[摘要] 目的 探讨支气管哮喘采用孟鲁司特钠联合布地奈德治疗临床疗效。方法 方便选取2011年1月―2016年12月收治的60例支气管哮喘患者作为对象,依据数字表法分组,各有30例。对照组用布地奈德治疗,联合组采用孟鲁司特钠联合布地奈德治疗。比较两组治疗效果、症状缓解时间、实验室指标。 结果 联合组支气管哮喘病情控制效果96.67%高于对照组73.33%,差异有统计学意义(P http://
[关键词] 支气管哮喘;孟鲁司特钠;布地奈德;肺功能
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2017)11(c)-0115-03
[Abstract] Objective This paper tries to investigate the clinical efficacy of montelukast sodium combined with budesonide in bronchial asthma. Methods 60 patients with bronchial asthma from January 2011 to December 2016 were convenient selected and divided into two groups, according to the number table, with 30 cases in each group. The control group was treated with budesonide, and the combination group was treated with montelukast sodium combined with budesonide. The treatment effect, symptom relief time, laboratory indicators of the two groups were compared. Results The control effect of bronchial asthma in the combined group was 96.67% higher than that in the control group of 73.33%,The difference was statistically significoits(P0.05),具有可比性。
1.2 方法
对照组用布地奈德(国药准字 H04130200)治疗,400 μg/次雾化吸入,2次/d。联合组采用孟鲁司特钠联合布地奈德治疗。布地奈德同上,孟鲁司特钠(国药准字H20083372)10 mg/次,睡前口服1次,两组患者均连续治疗4周。
1.3 观察指标
比较两组支气管哮喘病情控制效果;咯痰、哮喘缓解时长、哮鸣音消失时长、住院时长;干预前后患者PET、FVC、外周血嗜酸粒细胞计数、IL-6。显效:症状、体征完全缓解,肺功能和炎症因子正常;有效:症状、体征减轻,肺功能和炎症因子好转;无效:症状、体征、肺功能和炎症因子无好转。支气管哮喘病情控制效果为显效、有效百分率之和[2]。 1.4 统计方法
采用SPSS 18.0统计学软件处理数据,计量资料用(x±s)表示,作t检验,计数资料用[n(%)]表示,采用χ2检验对比,P0.05);干预后联合组FVC、PET(0.81±0.21)L/s 、(3.28±0.61)L高于对照组(0.37±0.15)L/s、(2.58±0.62)L,白介素-6、外周血嗜酸粒细胞计数(0.10±0.01)×109/L、(23.21±10.6)μg/L低于对照组(0.21±0.04)×109/L、(32.38±10.69)μg/L,差异有统计学意义(P参考文献]
[1] 黄肖梅,黄卫娟,陈建江,等.沙美特罗替卡松单用与丙酸氟替卡松联合孟鲁司特钠治疗儿童中度持续哮喘的疗效比较[J].中国药房,2016,27(23):3240-3243.
[2] 邓俊,杨艳,梁宇佳,等.孟鲁司特对哮喘大鼠气道炎症的调控作用及其机制[J].山东医药,2016,56(24):34-36.
[3] Lillienberg L,Andersson E,Janson C,et al.Occupational exposure and new-onset asthma in a population-based study in northern Europe(RHINE)[J].The Annals of Occupational Hygiene: An International Journal Published for the British Occupational Hygiene Society,2013,57(4):482-492.
[4] 吕青青,金小红,李绍波,等.孟鲁司特对哮喘大鼠肺组织嗜铬蛋白A表达的影响[J].预防医学,2016,28(8):781-784.
[5] Sharon D Dell,Michael Jerrett,Bernard Beckerman,et al.Presence of other allergic disease modifies the effect of early childhood traffic-related air pollution exposure on asthma prevalence[J].Environment international,2014,65(Apr.):83-92.
[6] 张晓丽,王学梅.吸入布地奈德联合盐酸西替利嗪和/或孟鲁司特钠治疗儿童过敏性鼻炎-哮喘综合征的效果对比[J].中国医药导报,2016,13(18):117-121.
[7] 马红梅,刘香莲.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的作用分析[J].中国实用医药,2015,10(1):350-353.
[8] 万江,罗望梅,郑申健,等.布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床效果[J].中国医院用药评价与分析,2016,16(8):1057-1059.
[9] 李玲,苟洪波,文亚娜,等.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效研究[J].重庆医学,2013,42(34):4198-4199.
[10] 吴小妹,蓝丽萍.孟鲁司特联合常规治疗哮喘患儿的疗效及对血清金属蛋白酶-9及其抑制因子-1水平的影响[J].中国药师,2016,19(7):1307-1308,1316.
[11] 王昕华,韩曙光,吕蕾,等.孟鲁司特联合酮替芬对哮喘患者血清TGF-β1、MCP-1、SDF-1水平的影?[J].疑难病杂志,2016,15(3):260-263.
[12] 魏晓红,程巍.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效分析[J].中国医药指南,2015,13(6):14-16.
(收稿日期:2017-08-25)